Insulin Cost Caps: What's Federal Law and What Varies

Medicare has capped insulin costs at $35 per month per covered product since January 1, 2023, but that federal cap applies only to Medicare, not to commercial insurance nationwide (HHS/ASPE). Separately, 29 states and the District of Columbia have their own insulin copay caps for state-regulated commercial plans, ranging from $25 to $100 for a 30-day supply (American Diabetes Association). Because coverage differs so much by plan type and state, it is worth comparing prescription prices for insulin regardless of which cap might apply to you.

The federal Medicare insulin cap

Under the Inflation Reduction Act, Medicare Part D enrollees have paid no more than $35 for a 30-day supply of each covered insulin product since January 1, 2023, with no deductible applied to insulin (HHS/ASPE). Since July 1, 2023, a similar cap applies to insulin delivered through a covered insulin pump under Medicare Part B.

For 2026, CMS finalized a slightly more precise formula: the cost-sharing amount for a covered insulin product is the lesser of $35, 25 percent of the drug's Medicare-negotiated maximum fair price, or 25 percent of the plan's negotiated price (CMS). In practice, this means some beneficiaries may pay less than $35 if the underlying negotiated price is low. Whatever you pay for insulin under this cap also counts toward Medicare's broader $2,100 annual out-of-pocket cap for 2026.

Why there is no nationwide cap for everyone

The $35 Medicare cap does not extend automatically to people with employer-sponsored or individual commercial insurance. Congress has repeatedly introduced legislation, including the Affordable Insulin Now Act and, more recently, a bipartisan bill sometimes called the INSULIN Act, to extend a similar $35 cap to private insurance nationwide. As of mid-2026, these proposals had not become law, though versions have passed one chamber of Congress at different points and remain an active area of legislative activity (The Hill; Endocrine Society). Because federal legislation in this area can move quickly, check current status before assuming a nationwide cap for commercial insurance exists.

State-level insulin caps fill some of the gap

In the absence of a nationwide commercial insurance cap, individual states have passed their own laws. As of 2026, 29 states and the District of Columbia cap insulin copays for state-regulated commercial health plans (American Diabetes Association). Cap amounts vary considerably:

Importantly, these state caps generally apply only to state-regulated fully insured plans. Self-funded employer plans governed by the federal ERISA law are typically not covered by state insulin caps, since federal law generally preempts state insurance regulation for those plans (Milliman analysis for Breakthrough T1D). This means two people in the same state, both with commercial insurance, may have very different insulin costs depending on whether their employer's plan is fully insured or self-funded.

What this means for you in practice

To figure out which rules apply to your insulin costs, check:

• Are you on Medicare? You already benefit from the $35 federal cap, with no deductible.
• Are you on Medicaid? Insulin is generally treated like other covered outpatient drugs under your state's Medicaid prescription copay rules, which cap nominal copays separately from the insulin-specific caps described here.
• Do you have commercial insurance through a state-regulated plan? Check whether your state has passed an insulin cap and what the cap amount is.
• Is your employer plan self-funded? State insulin caps likely do not apply, though your employer may still choose to offer similar cost protections voluntarily.
• Are you uninsured? Neither the federal Medicare cap nor most state commercial caps apply to you directly, so cash price comparison and manufacturer assistance programs become more important.

Compare prescription prices on BetterBuyRx for insulin products, since cash prices can vary meaningfully between pharmacies even before any insurance-based cap applies.

Why list price and cap amount are not the same thing

A cost-sharing cap limits what you personally pay at the pharmacy counter, but it does not change a drug's underlying list price or what your insurer or Medicare pays behind the scenes. This distinction matters if you are comparing insulin costs across different coverage situations: someone with a $35 Medicare cap and someone paying a pharmacy's full cash price for the same insulin product can see very different numbers, even though the manufacturer's list price is identical. It also explains why insurers and pharmacy benefit managers can debate insulin pricing policy separately from the caps that protect individual patients, since rebates, negotiated prices, and list prices operate on a different track than the copay cap itself (KFF).

Options if you are uninsured or your plan is not covered by a cap

Some insulin manufacturers offer their own patient assistance or discount programs directly to uninsured or underinsured patients, and some states run separate programs aimed at emergency insulin access. Because these programs change based on funding and manufacturer policy, ask your prescriber, pharmacist, or check nonprofit assistance directories for current options. A prescription discount card may also lower your cash price at certain pharmacies.

Search your medication on BetterBuyRx to see how insulin prices compare across nearby pharmacies before you assume a specific price applies to you.